We assessed the
in vitro
antiviral activity of remdesivir and its parent nucleoside GS-441524, molnupiravir and its parent nucleoside EIDD-1931 and the viral protease inhibitor nirmatrelvir against the ancestral SARS-CoV2 strain and the five variants of concern including Omicron. VeroE6-GFP cells were pre-treated overnight with serial dilutions of the compounds before infection. The GFP signal was determined by high-content imaging on day 4 post-infection. All molecules have equipotent antiviral activity against the ancestral virus and the VOCs Alpha, Beta, Gamma, Delta and Omicron. These findings are in line with the observation that the target proteins of these antivirals (respectively the viral RNA dependent RNA polymerase and the viral main protease Mpro) are highly conserved.
Drugs targeting SARS-CoV-2 could have saved millions of lives during the COVID-19
pandemic, and it is now crucial to develop inhibitors of coronavirus replication in
preparation for future outbreaks. We explored two virtual screening strategies to find
inhibitors of the SARS-CoV-2 main protease in ultralarge chemical libraries. First,
structure-based docking was used to screen a diverse library of 235 million virtual
compounds against the active site. One hundred top-ranked compounds were tested in
binding and enzymatic assays. Second, a fragment discovered by crystallographic
screening was optimized guided by docking of millions of elaborated molecules and
experimental testing of 93 compounds. Three inhibitors were identified in the first
library screen, and five of the selected fragment elaborations showed inhibitory
effects. Crystal structures of target–inhibitor complexes confirmed docking
predictions and guided hit-to-lead optimization, resulting in a noncovalent main
protease inhibitor with nanomolar affinity, a promising in vitro pharmacokinetic
profile, and broad-spectrum antiviral effect in infected cells.
Compound repurposing
is an important strategy for the identification
of effective treatment options against SARS-CoV-2 infection and COVID-19
disease. In this regard, SARS-CoV-2 main protease (3CL-Pro), also
termed M-Pro, is an attractive drug target as it plays a central role
in viral replication by processing the viral polyproteins pp1a and
pp1ab at multiple distinct cleavage sites. We here report the results
of a repurposing program involving 8.7 K compounds containing marketed
drugs, clinical and preclinical candidates, and small molecules regarded
as safe in humans. We confirmed previously reported inhibitors of
3CL-Pro and have identified 62 additional compounds with IC50 values below 1 μM and profiled their selectivity toward chymotrypsin
and 3CL-Pro from the Middle East respiratory syndrome virus. A subset
of eight inhibitors showed anticytopathic effect in a Vero-E6 cell
line, and the compounds thioguanosine and MG-132 were analyzed for
their predicted binding characteristics to SARS-CoV-2 3CL-Pro. The
X-ray crystal structure of the complex of myricetin and SARS-Cov-2
3CL-Pro was solved at a resolution of 1.77 Å, showing that myricetin
is covalently bound to the catalytic Cys145 and therefore inhibiting
its enzymatic activity.
Background: Favipiravir and Molnupiravir, orally available antivirals, have been reported to exert antiviral activity against SARS-CoV-2. First efficacy data have been recently reported in COVID-19 patients. Methods: We here report on the combined antiviral effect of both drugs in a SARS-CoV-2 Syrian hamster infection model. The infected hamsters were treated twice daily with the vehicle (the control group) or a suboptimal dose of each compound or a combination of both compounds. Findings: When animals were treated with a combination of suboptimal doses of Molnupiravir and Favipiravir at the time of infection, a marked combined potency at endpoint is observed. Infectious virus titers in the lungs of animals treated with the combination are reduced by »5 log10 and infectious virus are no longer detected in the lungs of >60% of treated animals. When start of treatment was delayed with one day a reduction of titers in the lungs of 2.4 log10 was achieved. Moreover, treatment of infected animals nearly completely prevented transmission to co-housed untreated sentinels. Both drugs result in an increased mutation frequency of the remaining viral RNA recovered from the lungs of treated animals. In the combotreated hamsters, an increased frequency of C-to-T mutations in the viral RNA is observed as compared to the single treatment groups which may explain the pronounced antiviral potency of the combination. Interpretation: Our findings may lay the basis for the design of clinical studies to test the efficacy of the combination of Molnupiravir/Favipiravir in the treatment of COVID-19. Funding: stated in the acknowledgment.
Paxlovid is the first oral antiviral approved for treatment of SARS-CoV-2 infection. Antiviral treatments are often associated with the development of drug-resistant viruses.
The SARS-CoV-2 main protease (3CLpro) has an indispensable role in the viral life cycle and is a therapeutic target for the treatment of COVID-19. The potential of 3CLpro-inhibitors to select for drug-resistant variants needs to be established. Therefore SARS-CoV-2 was passaged in vitro in the presence of increasing concentrations of ALG-097161, a probe compound designed in the context of a 3CLpro drug discovery program. We identified a combination of amino acid substitutions in 3CLpro (L50F E166A L167F) that is associated with > 20x increase in EC50 values for ALG-097161, nirmatrelvir (PF-07321332) and PF-00835231. While two of the single substitutions (E166A and L167F) provide low-level resistance to the inhibitors in a biochemical assay, the triple mutant results in the highest levels of resistance (6- to 72-fold). All substitutions are associated with a significant loss of enzymatic 3CLpro activity, suggesting a reduction in viral fitness. Structural biology analysis indicates that the different substitutions reduce the number of inhibitor/enzyme interactions while the binding of the substrate is maintained. These observations will be important for the interpretation of resistance development to 3CLpro inhibitors in the clinical setting.
There is an urgent need for potent and selective antivirals against SARS-CoV-2. Pfizer developed PF-07321332 (PF-332), a potent inhibitor of the viral main protease (Mpro, 3CLpro) that can be dosed orally and that is in clinical development. We here report that PF-332 exerts equipotent in vitro activity against the four SARS-CoV-2 variants of concerns (VoC) and that it can completely arrest replication of the alpha variant in primary human airway epithelial cells grown at the air-liquid interface. Treatment of Syrian Golden hamsters with PF-332 (250 mg/kg, twice daily) completely protected the animals against intranasal infection with the beta (B.1.351) and delta (B.1.617.2) SARS-CoV-2 variants. Moreover, treatment of SARS-CoV-2 (B.1.617.2) infected animals with PF-332 completely prevented transmission to untreated co-housed sentinels.
Transient receptor potential (TRP) cation channels play diverse roles in cellular Ca 2+ signaling. First, as Ca 2+ -permeable channels that respond to a variety of stimuli, TRP channels can directly initiate cellular Ca 2+ signals. Second, as nonselective cation channels, TRP channel activation leads to membrane depolarization, influencing Ca 2+ influx via voltage-gated and store-operated Ca 2+ channels. Finally, Ca 2+ modulates the activity of most TRP channels, allowing them to function as molecular effectors downstream of intracellular Ca 2+ signals.Whereas the TRP channel field has long been devoid of detailed channel structures, recent advances, particularly in cryo-electron microscopy-based structural approaches, have yielded a flurry of TRP channel structures, including members from all seven subfamilies. These structures, in conjunction with mutagenesis-based functional approaches, provided important new insights into the mechanisms whereby TRP channels permeate and sense Ca 2+ . These insights will be highly instrumental in the rational design of novel treatments for the multitude of TRP channel-related diseases.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.